Microbix Biosystems (TSE:MBX) Sets New 12-Month High – Here’s What Happened

Microbix Biosystems Inc. (TSE:MBX)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as C$0.32 and last traded at C$0.31, with a volume of 22000 shares changing hands. The stock had previously closed at C$0.31.

Microbix Biosystems Price Performance

The company has a debt-to-equity ratio of 27.03, a quick ratio of 5.57 and a current ratio of 5.35. The business has a 50-day simple moving average of C$0.30 and a 200 day simple moving average of C$0.26. The firm has a market cap of C$42.63 million, a P/E ratio of -7.56 and a beta of 0.72.

Microbix Biosystems (TSE:MBX) last issued its quarterly earnings data on Thursday, May 14th. The company reported C($0.01) earnings per share for the quarter. Microbix Biosystems had a negative return on equity of 21.02% and a negative net margin of 38.62%.The business had revenue of C$3.38 million during the quarter. On average, analysts anticipate that Microbix Biosystems Inc. will post 0.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Martin Marino purchased 115,000 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were acquired at an average price of C$0.28 per share, for a total transaction of C$32,200.00. Following the completion of the acquisition, the director directly owned 2,000,167 shares in the company, valued at approximately C$560,046.76. The trade was a 6.10% increase in their position. Insiders acquired a total of 251,000 shares of company stock valued at $68,355 over the last ninety days. Company insiders own 14.00% of the company’s stock.

Microbix Biosystems Company Profile

Microbix Biosystems Inc creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs ¿ ) and reference materials (QUANTDx ¿ ) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows.